Switch from cyclosporine A to mycophenolate mofetil in nephrotic children.
Nephrotoxicity is a well-known adverse effect of cyclosporine A (CyA) treatment in children with steroid-dependent (SD) and steroid-resistant (SR) nephrotic syndrome (NS). We analyzed nine children (age: 3.3-15.7 years, two girls) with SD or SR NS who experienced a significant decrease in their GFR under CyA treatment as measured by inulin clearance (C(IN)). Mycophenolate mofetil (MMF) was introduced progressively until doses of 1 g/1.73 m(2) twice daily were reached. CyA treatment was stopped after introduction of MMF and oral steroids were reduced if possible. After a median follow up of 261 days, no adverse effects of MMF such as diarrhea or hematological anomalies occurred in our patients. After switching from CyA to MMF, those children with SD NS remained in remission without proteinuria and those with SR NS did not show any significant changes in their residual proteinuria. The serum protein level did not change significantly in any of the children analyzed. GFR increased from a mean of 76.9+/-4.8 to 119.9+/-5.9 mL/1.73 m(2) per min (P<0.001). Oral steroid treatment could be reduced from a median [range] prednisone dose of 0.85 [0.26-2.94] mg/kg/d pre-MMF to 0.29 [0-1.1] mg/kg per day (P=0.026), and blood pressure decreased moderately after CyA withdrawal, but the difference did not reach statistical significance. We conclude that a switch from CyA to MMF seems to be safe for children with SDNS and SRNS in terms of side effects as well as disease control, at least in the short term. Interruption of CyA treatment lead to rapid amelioration of kidney function in these children, often associated with steroid sparing, which may lead to additional benefit for growth velocity, blood pressure and physical appearance.
Ulinski
Tim
T
Department of Pediatrics, Nephrology Unit, Hôpital Edouard Herriot, 69437 Lyon Cedex 03, France.
Dubourg
Laurence
L
Saïd
Marie Hélène
MH
Parchoux
Bernadette
B
Ranchin
Bruno
B
Cochat
Pierre
P
D000293:Adolescent; D002648:Child; D002675:Child, Preschool; D016572:Cyclosporine / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D005886:Gingival Hypertrophy / Q000139:chemically induced; D005919:Glomerular Filtration Rate / Q000187:drug effects; D006801:Humans; D006983:Hypertrichosis / Q000139:chemically induced; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D007668:Kidney / Q000187:drug effects; D008297:Male; D009173:Mycophenolic Acid / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D009404:Nephrotic Syndrome / Q000188:drug therapy* / Q000503:physiopathology; D019233:Retreatment; D016896:Treatment Outcome
D007166:Immunosuppressive Agents; D016572:Cyclosporine; D009173:Mycophenolic Acid
Springer Semin Immunopathol. 1993;14 (4):353-80
8322167
J Am Soc Nephrol. 2000 Feb;11(2):283-90
10665935
Pediatr Nephrol. 2003 Aug;18(8):772-7
12811652
Pediatr Nephrol. 2000 Mar;14(3):214-7
10752760
J Investig Allergol Clin Immunol. 1993 Jan-Feb;3(1):8-18
8281333
Pediatr Nephrol. 2004 Jan;19(1):101-4
14753204
Transplantation. 1999 Aug 15;68(3):411-8
10459546
Transplant Proc. 1991 Apr;23 (2 Suppl 2):15-8
2063416
Transplantation. 1995 Nov 27;60(10 ):1143-8
7482723
Nephrol Dial Transplant. 1999 Jan;14 (1):58-63
10052478
Pediatr Nephrol. 2003 Aug;18(8):833-7
12774223
Transplant Proc. 1993 Jun;25(3 Suppl 2):67-70
8516949
Agents Actions Suppl. 1993;44:165-88
8372727
Kidney Int. 1997 May;51(5):1583-9
9150476
Ann N Y Acad Sci. 1993 Nov 30;696:108-22
7509129
J Am Soc Nephrol. 1998 Dec;9(12 ):2272-82
9848781
Nephrol Dial Transplant. 2002 Nov;17 (11):2011-3
12401863